Yannis M. Paulus, MD
W. K. Kellogg Eye Center
Tuesday October 10th, 6:30 p.m.
Location of Seminar: Room 1123 Lurie Biomedical Engineering Building (LBME), 1101 BEAL AVE, Ann Arbor, MI
In 1961, one year after the first laser was developed, laser therapy of the eye was described. For over 55 years, laser therapies have played a critical role in the treatment of numerous eye diseases, including proliferative diabetic retinopathy, diabetic macular edema, retinal vein occlusions, sickle cell retinopathy, tumors, retinal tears, glaucoma, and secondary capsule opacification cataracts. Significant advances have been made in laser technology and the molecular understanding of laser–tissue interactions to maximize the therapeutic effect while minimizing side-effects. We will discuss conventional panretinal photocoagulation and focal laser therapy in addition to new and emerging technologies, including: patterned scanning laser, selective retinal therapy, subthreshold micropulse laser, nanosecond pulse duration laser, photo-mediated ultrasound therapy, navigated laser, and real-time image-guided laser therapy. Selective and shorter pulse duration therapy can significantly reduce the collateral damage, patient pain, and complication risk while increasing the therapeutic effect and safety window. Continuing innovations in laser technology and progress in understanding laser-tissue interactions mean that lasers will continue to play a critical role in treating eye diseases for many years to come.